| Description | Isothiafludine (NZ-4) is an orally active anti-HBV compound that acts by blocking the encapsulation of pre-genomic RNA (pgRNA) and interfering with nucleosome capsid assembly, and is used in the study of HBV infections. |
| In vivo | 在 DHBV 感染的鸭模型中，Isothiafludine（25-100 mg/kg；口服，连续 15 天）在第 15 天抑制了血清中的 DHBV DNA[1]。 |
| Synonyms | W 28 F, NZ4, NZ‐4, NZ 4, W-28-F |
| molecular weight | 375.48 |
| Molecular formula | C18H18FN3OS2 |
| CAS | 960527-22-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Yang L, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin. 2014 Mar;35(3):410-8. 2. Yang L, Wang YJ, Chen HJ, Shi LP, Tong XK, Zhang YM, Wang GF, Wang WL, Feng CL, He PL, Xu YB, Lu MJ, Tang W, Nan FJ, Zuo JP. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation. Antiviral Res. 2016 Jan;125:25-33. doi: 10.1016/j.antiviral.2015.11.004. PubMed PMID: 26611395. |